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In contrast to the once dominant tumour-centric view of cancer, increasing attention is now being paid to the tumour
microenvironment (TME), generally understood as the elements spatially located in the vicinity of the tumour. Thinking in
terms of TME has proven extremely useful, in particular because it has helped identify and comprehend the role of nongenetic
and noncell-intrinsic factors in cancer development. Yet some current approaches have led to a TME-centric view, which is no
less problematic than the former tumour-centric vision of cancer, insofar as it tends to overlook the role of components located
beyond the TME, in the ‘tumour organismal environment’ (TOE). In this minireview, we highlight the explanatory and
therapeutic shortcomings of the TME-centric view and insist on the crucial importance of the TOE in cancer progression.
Introduction: Why Going Beyond the TME?
Cancer research was dominated by a tumour-centric view for a
long time, which essentially focused on deciphering the intrinsic
characteristics of tumour cells with little, if any, attention paid to
their surrounding environment. However, since the 1970s, evi-
dence has accumulated that the tumour microenvironment (TME)
plays a key role in fostering or restraining tumour development,1,2
a view that has now become prevalent.3 Indeed, the notion that
cancers arise and develop in speciﬁc interacting contexts has
gained undeniable traction in recent years.4–9
Thinking in terms of TME has proven extremely useful, in par-
ticular because it has helped emphasise the importance of non-
genetic and noncell-intrinsic factors in cancer development. Yet,
the recent focus on the TME has led, in parallel, to a ‘TME-centric’
view of cancer, namely, a view centred on the role of the tumour
and its immediate surroundings in cancer progression. In a recent
study, we have discussed the spatial boundaries of the TME, and
have suggested distinguishing different layers of the tumour envi-
ronment, from the very local environment to the entire organism.
We have dubbed the latter the ‘tumour organismal environment’
(TOE).10
In this minireview, we examine the latest compelling evidence
in favour of the causal role of the TOE in tumour development and
argue on that basis that the TME-centric view is too narrow to
accurately reﬂecting the complexities of the interacting networks
involved in tumour development. As an important corollary,
although TME-centred anticancer therapies have led to promising
results, many of these approaches face shortcomings11 in part
because they fail to take into consideration the signiﬁcant inﬂuence
of these distant factors commonly excluded from the TME.12 It is
therefore essential to look beyond the TME, and consider these dis-
tant actors, which are pivotal for cancer progression, and to explore
the critical interactions that occur between local and nonlocal
components.
The Key Role of the TOE
A few years ago,McAllister andWeinberg reviewed data indicating
that tumours can affect distant sites that might in turn exert effects
on primary or secondary tumour development, thus providing
empirical support to the view of cancer as a systemic disease.13
Here, we expand this discussion by reviewing the latest evidence
highlighting the potential involvement of additional distant factors,
in particular some systemic immune components, the nervous sys-
tem and themicrobiota.We adopt a broader view with the concept
of TOE, which includes elements that might not be modiﬁed by
the tumour but nonetheless inﬂuence it (Fig. 1). We argue that dis-
tinguishing the TOE from the TME is important, ﬁrst because
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distant elements of the TOE (which for some of them may never
enter the TME) can critically affect tumour development, and sec-
ond because mechanisms operating locally are generally different
from those operating at a distance.
Role of the immune system beyond the TME
Although many immune cells and soluble factors they produce
have been identiﬁed within the tumour beds, the immune system
constitutes an example of a system that can be localised at a dis-
tance from the tumour, and nonetheless exert an important impact
on its progression and dissemination. We explore here four major
aspects of this phenomenon: the role of lymph nodes, spleen and
bone marrow, as well as the truly systemic inﬂuence (i.e. whole
organism-level) of some immune processes.
Tumour-draining lymph nodes (TDLNs) are a case in point of
structures involved in antitumour immunity but localised outside
tumour boundaries and therefore usually not considered as part of
the TME. These sites, in which tumour antigens are ﬁrst presented
to naive T cells, are key determinants in setting the course of
immune responses, as they are the primary locations where the
mechanisms of both anticancer immunity and tumour-induced
immunosuppression are integrated. For instance, dendritic cell
(DC) migration to lymph nodes is critical for the efﬁciency of
immunotherapies such as DC vaccines. As an example, Mitchell
and colleagues demonstrated that preconditioning the vaccine site
with the potent recall antigen tetanus/diphtheria toxoid generated
local inﬂammatory responses leading to improved DC migration
to lymph nodes (vaccine-site draining LNs as well as more distant
LNs), and greatly enhanced the efﬁcacy of their DC vaccine both in
a mouse model of glioblastoma and in their patient cohort.14
TDLNs may have a causal effect on what will occur at the tumour
site, and they constitute potential therapeutic targets of the micro-
environment.15 For instance, accumulation of regulatory T cells in
TDLNs of colorectal patients, but their lack of accumulation at the
tumour site, has been correlated with disease progression.16 More-
over, TDLNs undergo changes as upstream tumour profoundly
alters functional characteristics of downstream lymph nodes.17,18
For example, the antigen-presenting cells that migrate from the
tumour site to the TDLNs are skewed toward a tolerogenic
phenotype.17 Furthermore, no tumour regression was observed
after immunotherapy in a spontaneous model of mammary
tumour whenmice were treated with FTY720, a component block-
ing the egress of cells from the lymph nodes.19 TDLNs can also
have an active role in tumour dissemination, as intralymphatic
blood vessels may serve as exit route for tumour metastasis in dif-
ferent organs,20,21 Furthermore, a premetastatic priming of LNs
can occur through the action of VEGF-C or other factors.22 Thus,
this indicates that the immune/lymphatic TOE not only partici-
pates in the modulation of the immune tolerance of the primary
tumour but also has a role in tumour dissemination.
To better understand the role of TDLNs in tumour progression,
it is illuminating to compare them with tertiary lymphoid organs
(TLOs). TLOs have a structure similar to that of lymph nodes, as
they are composed of T cells and mature dendritic cells in the
T-cell areas close to a B cell follicle and they also have similar func-
tions such as T-cell priming and activation by antigen-presenting
cells.23,24 TLOs, described in close vicinity of tumour mass or even
within the tumour, are usually considered as an active part of the
TME often associated with good prognosis,25 as highlighted in a
recent review,26 even though regulatory T cells can also accumulate
in TLOs and then suppress antitumour immunity.27 The key point
here is that TLOs and TDLNs sharemany features, structurally and
functionally, somuch so that the inclusion of TLOs but not TDLNs
in the TME is based only on their location, not on their causal inﬂu-
ence on tumour progression. If one focuses on how some bodily
components causally inﬂuence the fate of the tumour, as we do
here, then it must be acknowledged that TDLNs are pivotal ele-
ments of the TOE and play amajor role in tumour progression.
Figure 1. Elements located far from the tumour microenvironment can
inﬂuence cancer progression. Investigations on cancer growth and
dissemination have tended to focus on the causal inﬂuence of elements
located within the tumour itself or in its immediate vicinity, that is, in
the tumour microenvironment (TME). Nevertheless, elements that do not
belong to the TME can sometimes have a major impact on cancer
progression, including the immune system, the nervous system, and the
microbiome. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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The spleen, as a main secondary lymphoid organ, represents
another example of a component of immunity located outside the
conventional boundaries of the TME but that still exerts a causal
inﬂuence on tumour development. Evidence for the role of spleen
cells in the control of malignancies has been provided by splenec-
tomy experiments. The outcome of such procedure remains dis-
puted, with some studies indicating that it may promote tumour
elimination (in part by removing immunosuppressive cells pro-
duced in the spleen) or conversely foster tumour development. For
instance, it has been reported that splenectomy enhances anti-
tumour immunity by restoring the effector antitumoural function
of T lymphocytes, which effectively improves immunotherapeutic
interventions.28 In this latter case, splenectomy is associated with
the removal of tumour-induced immunosuppressive CD11b+Gr1+
cells located outside the microenvironment itself. Importantly,
these observations suggest that the distant environment (the spleen
in this case) can represent a useful therapeutic target to affect pri-
mary tumour progression. Similar ﬁndings were reported in other
cancer types.29,30 Along these lines, increased risk of malignancies
has been observed in follow-up studies of patients subjected to
splenectomy.31,32 Of note, in some reports, a tumour-promoting
effects of splenectomy has been observed, associated with increased
number of FoxP3+ regulatory T cells at themetastatic sites.33
The bone marrow environment and the TME represent two
spatially distant entities. However, the crosstalk between these two
compartments signiﬁcantly affects cancer development, including
the metastatic process, at different levels and through a multitude
of mechanisms. Many tumour-derived growth and immunosup-
pressive factors produced within the TME [for instance,
granulocyte-colony stimulating factor (G-CSF) and transforming
growth factor β (TGFβ), as well as chemokines such as CCL2] can
circulate systemically and impact the haematopoietic compart-
ment, resulting in the production of immunosuppressive cells from
haematopoietic precursors. These tumour-promoting cells may
home to the TME, where they promote angiogenesis, invasion and
metastasis, to the premetastatic sites, or to the secondary lymphoid
organs where they impair the priming and development of T-cell
dependent antitumor immune responses.34–37 In addition, it is
noteworthy that the bone marrow has been reported as an impor-
tant site for the priming of tumour antigen-speciﬁc CD4+ and
CD8+ T lymphocytes which are ultimately involved in antitumour
immunity and in the control of cancer development.38 Moreover,
the bone marrow can play an intermediate causal role between dis-
tant tumours, referred to as ‘systemic instigation’. Malignant
tumours can stimulate, through the recruitment of haematopoietic
cells (Granulin+ Sca1+cKit−CD45+), the growth of distant tumours
that would otherwise be indolent.39 Taken together, these observa-
tions about lymph nodes, the spleen and bone marrow further
advocate for the existence of causal elements not located within the
TME but which substantially affect cancer development. Along
these lines, it is noteworthy thatmany immune cells and/or the sol-
uble factors they secrete circulate through the bloodstream from
one site to another (e.g. from the bone marrow to the lymph
nodes), thus being spatially localised outside the TME but still
contributing to tumour development. Immune cells in the circula-
tion also produce proinﬂammatory or antiinﬂammatory cytokines,
whichmay affect directly or indirectly tumour growth.
In addition to its activities associated with speciﬁc organs, the
immune system can have a ‘systemic’ activity, in which case it
exerts its functions at the level of the whole organism. Inﬂamma-
tion is considered to promote tumour progression and has even
been included in the 2000s among the ‘hallmarks of cancer’.7,40
Systemic inﬂammation can even play a role at preneoplastic stages,
as highlighted by a recent study showing that patients with athero-
sclerosis treated using IL-1β (an inﬂammatory cytokine) blocking
antibodies have lower incidence of lung cancer than patients
receiving placebo.41 Moreover, using systems analysis of a mouse
model of cancer, Spitzer et al. demonstrated that tumour eradica-
tion after immunotherapy requires immune activation in the
periphery.19 Thereby, the authors highlighted the importance of a
coordinated systemic antitumour immune response for effective
immunotherapy.
It is also noteworthy that several tumour-derived factors can
exert cancer-promoting effects at distance of the TME. For
instance, we have already outlined hereinabove that cytokines such
as TGFβ or G-CSF can promote the production of protumoural
immunosuppressive cells in the bone marrow.34–37 Other such
examples include tumour-derived exosomes which can colonise
speciﬁc organ sites, prepare premetastatic niches,42 and may pro-
mote immunosuppression and impair antitumour immune
responses in premetastatic organs (notably through their ability to
impair T-cell proliferation and natural killer cell cytotoxic func-
tion).43 Tumour-derived exosomes may also migrate to the lymph
nodes and inﬂuence tumour development.44
The effects of systemic factors such as exercise, age, diet, adipos-
ity and sex on the immune system are now better understood, and,
as shown in a recent review,26 key research is currently underway
to determine how these various factors directly affect the quality of
the antitumor immune response. Indeed, factors such as inﬂam-
mation, growth factors, cytokines and chemokines, in addition to
their local inﬂuence on the TME, are increasingly shown to have
important systemic immune-mediated effects on tumour growth
and dissemination.26
Role of the nervous system beyond the TME
The nervous system also connects cancer cells to the whole organ-
ism, and recent emphasis has been put on what is now called ‘neu-
rogenic control’ or ‘neural regulation’ of tumour development.
Both the sympathetic and the parasympathetic nervous systems
have been causally implicated in cancer initiation and progres-
sion.45 The interaction of the nervous system with cancer cells can
be either direct or mediated by a remodelling of the immune or
vascular microenvironment.46
Animal model studies have proved that behavioural stress can
accelerate the progression of different cancer types (breast, pros-
tate, ovary, brain, skin, pancreas, as well as some haematopoietic
cancers such as leukaemia).47 Stress-induced biological effects can
be efﬁciently blocked by β-adrenergic antagonists and mimicked
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by pharmacologic β-agonists in many of these models. Moreover,
different cellular and molecular mechanisms by which the sympa-
thetic nervous system can inﬂuence tumour progression have been
identiﬁed, including DNA repair, oncogene activation, inﬂamma-
tion and immune response, haematopoiesis, angiogenesis, cell sur-
vival and apoptosis.47 Several observational epidemiologic studies
have documented associations between exposure to β-adrenergic
antagonists and reduced progression of some cancers,48–51 though
some inconsistencies exist,52,53 which suggests that randomised
controlled studies are needed.
Many investigations have focused on the direct interaction
between cancer cells and the local nervous system. However, in the
haematopoietic system, the sympathetic nervous system connects
haematopoietic stem cells (HSCs) to the external environment:
maintenance and trafﬁcking of HSCs show circadian oscillations
that are regulated by the sympathetic nervous system through
secretion of noradrenaline, activation of β3-adrenergic receptor,
degradation of Sp1 and downregulation of CXCL12, which is mod-
ulated by photic cues that are transmitted from the eye to the sup-
rachiasmatic nucleus through the retinal–hypothalamic tract.54,55
Degradation of the sympathetic nervous system of the bone mar-
row, through the destruction of Schwann cells by leukemic stem
cells and monocyte secretion of IL-1, promotes the development of
myeloproliferative neoplasm by giving mutated cells an advantage
over normal HSCs.56 This local degradation disrupts the more sys-
temic regulation of haematopoiesis by the sympathetic nervous
system.
Neural control of tumour development is observed not only in
haematological malignancies but also in solid tumours. For exam-
ple, the development of prostate cancers is signiﬁcantly controlled
by the autonomous nervous system.57 Denervation with Botox sig-
niﬁcantly reduces prostate tumour development and leads to
increased tumour cell apoptosis.58 Similar observations have been
made in the case of gastric tumorigenesis: in mouse models of gas-
tric cancer, it was shown that surgical or pharmacological denerva-
tion of the stomach reduced signiﬁcantly tumour incidence and
progression, but in the denervated portion of the stomach exclu-
sively. Moreover, tumour stage in gastric cancer patients correlated
with neural density and activated Wnt signalling, and vagotomy
diminished the risk of gastric cancer. The authors propose that
vagal innervation contributes to gastric tumorigenesis via M3
receptor-mediatedWnt signalling in the stem cells, and that dener-
vation could represent a feasible strategy for the control of gastric
cancer.59
At a molecular level, β-adrenergic receptors play an important
role in neurogenic effects on cancer,47 and β-blocking agents are
able to inhibit metastasis development. It was shown that tumour
cell migration is regulated by signal substances of the environment
including chemokines and neurotransmitters. More speciﬁcally,
after the initial demonstration that the migration of breast, pros-
tate and colon carcinoma cells was enhanced by the stress-related
neurotransmitter norepinephrine in vitro and that this effect could
be inhibited by the β-blocker propranolol, it was later shown that
this neurotransmitter-driven regulationwas relevant in vivo.60
Taken together, these results highlight the long-range effects of
the nervous system on tumour development andmetastasis.
The increasingly appreciated role of the microbiome
Recent research has revealed that another, largely unexpected,
actor can inﬂuence cancer development well beyond the site of the
TME, namely, the microbiome.61 First, it has been reported that
the microbiome plays a role in carcinogenesis not only locally but
also at distant sites.12,62 The inﬂuence can be direct, for example
when microbes provide toxic metabolites or oncogenic products,
or indirect, in particular when microbes induce inﬂammation or
immunosuppression.61 Faecal microbial transplantation (FMT)
can transfer the neoplasia-prone phenotype from knockout mice
lacking some immune-relevant genes.
A second and more recent series of observations indicate that
the microbiome can inﬂuence how the host responds to anticancer
therapies. Several of these therapies, including chemotherapy and
anti-CTLA-4, anti-PD1 and anti-PDL1 immunotherapies, show
reduced efﬁcacy in germ-free mice as well as in mice treated with
broad-spectrum antibiotics (frequently used clinically in cancer
patients), or in mice lacking speciﬁc bacteria that stimulate the
immune system.63–67 The causal relationship between the domi-
nance of distinct commensals and the efﬁcacy of anticancer thera-
pies in these examples has been signiﬁcantly strengthened by
mouse cohousing experiments or oral gavage with deﬁned species.
Studies in bothmice and humans suggest that the administration of
antibiotics before or during anticancer therapies (which is frequent
in the clinic) might well be deleterious. In patients, it was observed
that bacteria generally associated with health and/or immune
stimulation had a positive impact on responses to some immuno-
therapies. Initial correlational observations were then conﬁrmed
causally, by FMT from patients to mice. Patient faecal samples were
transferred into germ-free or antibiotics-treated speciﬁc-pathogen-
free mice, that subsequently were inoculated with mouse syngeneic
tumours and then treated with monoclonal antibodies to CTLA-4
and/or PD-1/PD-L1. The key observation was that ‘responding’
and ‘nonresponding’ phenotypes could be transferred fromhumans
to mice, and some distinct bacteria playing a major role in this pro-
cess were identiﬁed (Bacteroides species in melanoma treated with
ipilimumab, Faecalibacterium in melanoma and Verrucomicro-
biacae in lung cancer patients treated with the PD-1 inhibitors
pembrolizumab or nivolumab).66–69 Mechanistically, several possi-
bilities are being investigated:61 stimulation of T-cell responses by
the microbiome; engagement of pattern recognition receptors in-
ducing proimmune or antiinﬂammatory effects, including perhaps
via the enteric nervous system;70 or production of small metabolites
thatmediate systemic effects on the host.
Overall, there is a growing consensus that the microbiome can
play a major role on both tumour growth and host responses to
cancer therapies, which conﬁrms that a distant actor, located well
beyond the TME, can causally inﬂuence cancer fate.
Collectively, the examples discussed hereinabove clearly dem-
onstrate that, despite the undeniable importance of the TME, ele-
ments located beyond the commonly deﬁned spatial boundaries of
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the TME can also play a crucial role in cancer progression.
Together, these remote components belong to the ‘TOE’. An exclu-
sive focus on the components present in the TME could have the
unwanted consequence that researchers might tend to neglect the
investigation of the causal inﬂuence on tumour progression and
dissemination of elements situated far from the tumour. Recent
research indicates that no element should be excluded a priori, and
certainly not on the sole basis of its distance to the tumour. Further
investigations are needed (and some are currently underway) to
determine whether remote components such as (among several
others) the endocrine system, nutrition, exercise and behavioural
factors including stress and emotion could play a role in tumour
development.71–76
The Therapeutic Beneﬁts of Considering the TOE
Why does it matter to consider elements that are located
beyond the TME and play a role in cancer development? We
propose that adopting the notion of TOE is essential not only
to apprehend and comprehend the multiple networks of recip-
rocal interactions and controls between tumours and the host
organism but also from a therapeutic point of view. Much
anticancer therapeutic research, including immunotherapies
and antiangiogenic therapies, aim at targeting the TME.77
Although this is, in many cases, a fruitful strategy, focusing on
the TME is problematic for two main reasons.
First, the efﬁcacy of TME-only centric therapeutics has often
been disappointing, as illustrated by the limited impact of anti-
angiogenic treatments.11 For example, one mechanism that can
promote evasive resistance to VEGF pathway inhibitors involves
protection of the tumour vasculature by recruiting proangiogenic
cells of the immune system (Fig. 2a).78,79 This probably reﬂects a
less important causal role of some speciﬁc factors than anticipated,
and/or a complex network of causal factors, withmany interactions
between them.80 Another explanation is the plasticity of pathways
where the cell machinery adapts to the constraints imposed by
therapy (hidden causality), as exempliﬁed by the induction of the
c-Met pathway under antiangiogenesis therapy, which promotes
tumour cell invasion.81
Second, TME-centric approaches tend to overlook the thera-
peutic importance of other, more distant, components.12 Here we
take two examples: the immune system and themicrobiome.
In the ﬁeld of oncoimmunology, strategies aimed at inducing
protective anticancer immunity primarily rely on the triggering of
antitumour immune responses in the secondary lymphoid organs,
where cytotoxic and helper T lymphocytes speciﬁc of tumour anti-
gens are produced and activated. In other words, the harnessing
and mobilisation of effector immune cells responsible for tumour
clearance occur outside the physical perimeter of the TME. Most
cancer vaccines such as tumour-derived peptides, protein–vaccine,
RNA or DNA encoding for tumour antigens, or dendritic cells, are
Figure 2. The role of the TOE in the therapeutic response. (a) Recruitment of pro-angiogenic immune cells by the TOE can promote resistance
to VEGF inhibitors; (b) The TOE can play an essential role in the efﬁcacy of some therapies such as cancer vaccines that lead to clonal
selection of tumour-speciﬁc T cells in secondary lymphoid structures, away from the tumour site itself; (c) The microbiota, localised within
the TOE, may also modulate the efﬁcacy of different therapies such as immunotherapies; (d) Therapies can also exhibit adverse effects on
the TOE: for instance, while killing cancer cells, chemotherapies can negatively impact the haematopoietic system, leading to a more pro-
tumorigenic TME. Abbreviations: T, tumour; TME, tumour microenvironment; TOE, tumour organismal environment. The tumour is represented
in yellow and the classical TME-centric view is in green, TME-centrism overlooks the involvement of the TOE (in blue) in the response to
therapies (in red). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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administered by subcutaneous, intradermal or intranodal routes,
and lead to clonal selection of tumour-speciﬁc T cells in secondary
lymphoid structures (in the TOE) away from the tumour site (the
TME) itself (Fig. 2b).82–84 Along these lines, immunosuppressive
cell elimination has been proven to foster anticancer immunity.
These beneﬁcial effects result not only from the depletion of sup-
pressive factors within the TME but also at the site of induction of
immune responses (the secondary lymphoid organs), where they
accumulate in substantial number during tumour progression. In
this context, regulatory immune checkpoint blockers (anti-CTLA4
and anti-PD1) act not only on immune effectors in tissues but also
at the early stages of T-cell response induction in the secondary
lymphoid tissues, thereby targeting elements located outside the
TME itself.85 Additionally, different approaches have been consid-
ered to maximise vaccine delivery to the draining lymph nodes,
one component of the TOE, with the goal of enhancing the prim-
ing of tumour-speciﬁc T lymphocytes, and thus antitumoural
immunity. Such strategies include the packaging of antigens and/or
adjuvants into bioengineered nanoparticles.86 A ﬁnal point to be
considered here concerning the distant action of the immune sys-
tem from a therapeutic point of view is the fact that current cancer
immunotherapies often have signiﬁcant adverse systemic effects,
which could potentially be alleviated therapeutically via the
targeting of elements located beyond the TME.
Another particularly illuminating example is the recently docu-
mented impact of the microbiome on anticancer therapies, in
agreement with mouse experiments already mentioned above. In
patients, it was observed that some bacteria had a positive impact
on responses to some immunotherapies. Initial correlational obser-
vations were then conﬁrmed experimentally by using FMT from
patients to mice.61 This demonstrates the possibility of a long-
distance impact on responses to anticancer treatment within the
broader context of the TOE, which opens up important avenues
for future research (Fig. 2c).
Crucially, the most promising therapies will certainly be those
able to combine the manipulation of both the traditionally deﬁned
TME and the TOE. For example, some therapies have deleterious
impact on haematopoiesis that can counterproductively participate
in tumour progression (Fig. 2d). To avoid these effects, additional
therapies such as 4-methylcatechol56 or administration of parathy-
roid hormones87 could be useful.34
These considerations therefore underline the fact that many
therapeutic interventions targeting elements clearly located outside
the tumour beds ultimately result in the control of cancer develop-
ment and dissemination. These data emphasise the need to not
solely focusing on the microenvironment located at the tumour
vicinity when designing anticancer therapies. Ongoing research on
potential clinical manipulation of various components of the TOE,
including the nervous system, nutrition and different other factors,
will determine to what extent therapeutic interventions on distant
components are likely to become generalised in the near future.
Conclusion
We have recently suggested a revision of the concept of the
TME by distinguishing multiple layers of the tumour environ-
ment.10 In our view, the classical TME constitutes only one
layer in this multilevel structure. More speciﬁcally, it corre-
sponds to the conﬁned (local) tumour environment, while the
TOE constitutes the outer layer of the tumour environment.
In this article, we provide mechanistic and clinical arguments
showing that many components of the TOE (such as the immune
system, the nervous system and the microbiome), and therefore
located beyond the traditionally deﬁned TME, can play a key role
in promoting or inhibiting tumour development (Figs. 1 and 2).
We content that reorienting current research towards the identiﬁ-
cation and quantiﬁcation of all causal factors, without overly
privileging the elements that surround the tumour, will lead to a
muchmore open-minded and productive approach to cancer. This
will also create new avenues for the exploration of interactions
between different layers of the tumour environment, especially
between the conﬁned tumour environment and the TOE. Such
exploration will undoubtedly be facilitated in the current era of
increasing adoption of next-generation techniques, particularly
single-cell sequencing and high-resolution data.
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